OraSure director David Shulkin to resign from board

OraSure Technologies, Inc. reported a change on its board of directors.

Accepted by SEC EDGAR 03/05/2026 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

OraSure Technologies, Inc. reported a change on its board of directors. On February 28, 2026, director David J. Shulkin, M.D. informed the board that he will resign as a director, including his role on the Compensation Committee, effective March 2, 2026.

The company stated that Dr. Shulkin’s decision to step down is not due to any dispute or disagreement with the board, the company, or its management. The board expressed its appreciation for his years of service and contributions. The filing was signed by President and Chief Executive Officer Carrie Eglinton Manner.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did OraSure Technologies (OSUR) disclose?

OraSure Technologies disclosed that director David J. Shulkin, M.D. will resign from the board. His resignation includes stepping down from the Compensation Committee, and it is effective March 2, 2026, according to the company’s current report on this governance change.

When is David J. Shulkin, M.D. leaving the OraSure Technologies board?

David J. Shulkin, M.D. is leaving the OraSure Technologies board effective March 2, 2026. He notified the board of his decision on February 28, 2026, giving formal advance notice of his resignation and related committee departure.

Did OraSure Technologies (OSUR) report any disagreement related to Dr. Shulkin’s resignation?

OraSure Technologies stated that Dr. Shulkin’s resignation is not due to any dispute or disagreement. The company specified there is no disagreement with the board, the company, or its management, characterizing the departure as amicable and orderly.

What board committee role is affected by David J. Shulkin’s resignation at OraSure?

In addition to leaving the board, David J. Shulkin, M.D. is resigning from the Compensation Committee. His decision removes him from both the full board and this key committee role, effective March 2, 2026, as disclosed by the company.

Who signed the OraSure Technologies report announcing the director resignation?

The report announcing the director resignation was signed by Carrie Eglinton Manner. She executed the filing in her capacity as President and Chief Executive Officer of OraSure Technologies, confirming the company’s authorization of the disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FALSE000111646300011164632026-02-282026-02-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 28, 2026    

OraSure Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware			001-16537			36-4370966
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

220 East First Street Bethlehem, Pennsylvania			18015-1360
(Address of Principal Executive Offices)			(Zip Code)

Registrant’s telephone number, including area code: 610-882-1820

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.000001 par value per share

OSUR

The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by a check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On February 28, 2026, David J. Shulkin, M.D. notified the board of directors (the “Board”) of OraSure Technologies, Inc. (the “Company”) of his decision to resign from his position as director, including his position as a member of the Compensation Committee of the Board, effective March 2, 2026. Dr. Shulkin's resignation is not due to any dispute or disagreement with the Board, the Company or its management.

The Board thanks Dr. Shulkin for his years of service and contributions to the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ORASURE TECHNOLOGIES, INC.
Date: March 5, 2026			By:			/s/ Carrie Eglinton Manner
						Carrie Eglinton Manner
						President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB